Major bleeds more likely with warfarin than NOACs
Note: The original headline on this story contained a typo conveying that NOACs carried a greater bleed risk. The headline has been amended.
Warfarin carries a higher risk of major bleeds than non-vitamin K antagonist oral anticoagulants (NOACs), experience at a Tasmanian hospital suggests.
A retrospective study of 2200 patients treated with antithrombotic therapy for AF at the Royal Hobart Hospital found those taking warfarin were 2.5 times more likely to be admitted for bleeding, compared with patients using NOACs.